Message boards : Rosetta@home Science : Interesting starting point for attacking Coronavirus
Previous · 1 . . . 3 · 4 · 5 · 6
Author | Message |
---|---|
Jim1348 Send message Joined: 19 Jan 06 Posts: 881 Credit: 52,257,545 RAC: 0 |
This is the real encouragement. https://news.yahoo.com/explainer-delta-variant-coronavirus-k417n-094930268.html |
Sid Celery Send message Joined: 11 Feb 08 Posts: 2119 Credit: 41,174,978 RAC: 11,583 |
The vaccine from this same platform, that's recently confirmed funding for Phase 3 trials, is looking to replace the annual flu jab based on 2 initial doses and 1 booster jab 2 years later. It's quite some advance on the mRNA vaccines that are currently out there, while dealing with flu at the same time I'm following it as close as I can. In that David Baker/Neil King video that's just come out, Neil King said he hopes it'll be available at the end of the year, if all goes well. The Phase 3 trial-funders talked more about the start of 2023. Either way, it's not far away, and if it really can handle all CV19 variants and several strains of flu, I'll expect quite some excitement about it when it goes through the approval process. Fingers crossed here. |
mikey Send message Joined: 5 Jan 06 Posts: 1895 Credit: 9,150,132 RAC: 4,252 |
The vaccine from this same platform, that's recently confirmed funding for Phase 3 trials, is looking to replace the annual flu jab based on 2 initial doses and 1 booster jab 2 years later. It's quite some advance on the mRNA vaccines that are currently out there, while dealing with flu at the same time Here too!! |
Sid Celery Send message Joined: 11 Feb 08 Posts: 2119 Credit: 41,174,978 RAC: 11,583 |
I'm following it as close as I can. In that David Baker/Neil King video that's just come out, Neil King said he hopes it'll be available at the end of the year, if all goes well. If I was paying more attention I'd have noticed I meant to write "the start of 2022"... #Doh |
robertmiles Send message Joined: 16 Jun 08 Posts: 1232 Credit: 14,269,631 RAC: 1,429 |
New Vaccine Blocks COVID-19 and Variants, Plus Other Coronaviruses https://corporate.dukehealth.org/news/new-vaccine-blocks-covid-19-and-variants-plus-other-coronaviruses Tofacitinib lowers risks for death, respiratory failure in COVID-19 pneumonia https://www.healio.com/news/rheumatology/20210623/tofacitinib-lowers-risks-for-death-respiratory-failure-in-covid19-pneumonia?utm_source=selligent&utm_medium=email&utm_campaign=news&M_BT=6620114329042 FDA issues EUA for tocilizumab to treat patients hospitalized with COVID-19 https://www.healio.com/news/rheumatology/20210625/fda-issues-eua-for-tocilizumab-to-treat-patients-hospitalized-with-covid19?utm_source=selligent&utm_medium=email&utm_campaign=news&M_BT=6620114329042 |
robertmiles Send message Joined: 16 Jun 08 Posts: 1232 Credit: 14,269,631 RAC: 1,429 |
What The Lambda COVID-19 Variant Means For Us Right Now https://www.huffpost.com/entry/lambda-covid-19-variant_l_60e71fb6e4b01d28533e6bb3 |
Sid Celery Send message Joined: 11 Feb 08 Posts: 2119 Credit: 41,174,978 RAC: 11,583 |
FDA issues EUA for tocilizumab to treat patients hospitalized with COVID-19 That's a bit weird, because it's been successfully used in the UK since January, along with another unpronounceable drug, sarilumab. Why the delay? BBC: Two more life-saving Covid drugs discovered - tocilizumab and sarilumab |
mikey Send message Joined: 5 Jan 06 Posts: 1895 Credit: 9,150,132 RAC: 4,252 |
FDA issues EUA for tocilizumab to treat patients hospitalized with COVID-19 Because the US and UK systems both have their own bureaucracy and refuse to cooperate with each other on drugs and their approval. SOME Dr's say it makes the systems redundant but most people think it's just time to take a look at streamlining the system. For example Dr's in the UK discovered if you analyze the bacteria from 2 people living in the same household eating similar things and one is overweight and the other is not that their gut bacteria is DIFFERENT. AND if you dehydrate that bacteria and give the thinner persons gut bacteria, in pill form, to the overweight person they GET THINNER, AND if you take the pill away they get heavy again!!! The UK now prescribes pills with thinner peoples gut bacteria in them to help severely overweight people get thinner, and IT WORKS with almost no side effects. YET the US refuses to even CONSIDER this as 'Science' and even do a test on it and continues doing Weight Loss Reduction Surgery on hundreds of thousands of pt's every year. |
Sid Celery Send message Joined: 11 Feb 08 Posts: 2119 Credit: 41,174,978 RAC: 11,583 |
FDA issues EUA for tocilizumab to treat patients hospitalized with COVID-19 I appreciate each country has their own decision-making and the UK results in my link hadn't been peer-reviewed at the time - and I'm aware of your example actually, which I kind of agree is pretty weird - but I thought everyone was looking at all possible treatments for CV19 and pick up on anything that looked positive because it seems to make such a big difference to deaths. To be fair, your link on Tofacitinib is completely new to me, though the reference to adverse reactions is worth looking at a lot more closely. |
mikey Send message Joined: 5 Jan 06 Posts: 1895 Credit: 9,150,132 RAC: 4,252 |
FDA issues EUA for tocilizumab to treat patients hospitalized with COVID-19 No some places have moved on to avoid duplicative efforts or ways that show they may end up in essentially the same place, it just means we are now multi-tasking in that we are trying to solve multiple diseases at the same time again. |
robertmiles Send message Joined: 16 Jun 08 Posts: 1232 Credit: 14,269,631 RAC: 1,429 |
Licensed drug could reduce SARS-CoV-2 infection by up to 70 per cent, reveals study https://www.eurekalert.org/news-releases/924448 |
Sid Celery Send message Joined: 11 Feb 08 Posts: 2119 Credit: 41,174,978 RAC: 11,583 |
BioRxiv: Robust de novo design of protein binding proteins from target structural information alone Is this related to the pre-clinical mini-binders tasks we ran here from April to August? If so, it seems to have been very successful |
Jim1348 Send message Joined: 19 Jan 06 Posts: 881 Credit: 52,257,545 RAC: 0 |
Is this related to the pre-clinical mini-binders tasks we ran here from April to August?They may be able to bind well, but there is the question of toxicology. I have heard it said that larger molecules are safer to use, since they are more likely to bind to just the target protein. Smaller molecules may also bind to useful proteins and cause adverse reactions. I don't know if that applies to the design technique that is used here, but it could be a general problem. |
dcdc Send message Joined: 3 Nov 05 Posts: 1831 Credit: 119,526,853 RAC: 6,993 |
One of the most exciting things for me, alongside protein design, is the possibility to scan a new protein against at least a large proportion, if not all, known proteins that it might interact with before investing too much in it. Presumably you can then make some changes and re-run the test. |
Jim1348 Send message Joined: 19 Jan 06 Posts: 881 Credit: 52,257,545 RAC: 0 |
One of the most exciting things for me, alongside protein design, is the possibility to scan a new protein against at least a large proportion, if not all, known proteins that it might interact with before investing too much in it. Presumably you can then make some changes and re-run the test. Wow. Testing is their big bottleneck. We might have had several cures by now if that could go faster. |
Sid Celery Send message Joined: 11 Feb 08 Posts: 2119 Credit: 41,174,978 RAC: 11,583 |
Is this related to the pre-clinical mini-binders tasks we ran here from April to August?They may be able to bind well, but there is the question of toxicology. Who knew proteins were so uncomplicated that they could accidentally bind to all manner of other proteins? There was me thinking it was pretty hard binding tightly to one. I think "mini" is a relative concept here. And I'm sure toxicity is a subject that's come up before. |
robertmiles Send message Joined: 16 Jun 08 Posts: 1232 Credit: 14,269,631 RAC: 1,429 |
[snip] Who knew proteins were so uncomplicated that they could accidentally bind to all manner of other proteins? There was me thinking it was pretty hard binding tightly to one. I'd say that it's hard to find something that will bind tightly to a SPECIFIC protein. However, there's quite a large number of types of proteins in the human body. Toxicology tests are needed to make sure that the substance being tested will not also binding tightly enough to any of these other proteins to cause problems. |
Jim1348 Send message Joined: 19 Jan 06 Posts: 881 Credit: 52,257,545 RAC: 0 |
And I'm sure toxicity is a subject that's come up before. It certainly has. This is how they view it on the Covid Moonshot project (Folding@home is part of it). All of the substances displayed on this site are designed to be biologically active. The prediction of toxic effects remains an extremely difficult problem. Therefore all materials described here should be treated as having high biological activity with a risk of severe toxicity which may include, but is not limited to: cardiac impairment up to and including the risk of causing cardiac arrest, irreversible liver or renal damage, carcinogenicity, mutagenicity, teratogenicity (risk to the unborn child) and, or generation of a severe allergic response. Unless otherwise stated, no material has been profiled for toxicological effects and therefore no materials should under any circumstances be synthesised and taken for any therapeutic or recreational effect by any person or for any other purpose. https://covid.postera.ai/covid/activity_data |
Sid Celery Send message Joined: 11 Feb 08 Posts: 2119 Credit: 41,174,978 RAC: 11,583 |
And I'm sure toxicity is a subject that's come up before. There you go. It's almost like making a point of it was redundant because it's built into everything they do. But, you do you... |
robertmiles Send message Joined: 16 Jun 08 Posts: 1232 Credit: 14,269,631 RAC: 1,429 |
Prophylaxis, treatment with probenecid inhibits 'virus replication' in COVID-19, flu, RSV https://www.healio.com/news/rheumatology/20210910/prophylaxis-treatment-with-probenecid-inhibits-virus-replication-in-covid19-flu-rsv?utm_source=selligent&utm_medium=email&utm_campaign=news&M_BT=6620114329042 |
Message boards :
Rosetta@home Science :
Interesting starting point for attacking Coronavirus
©2024 University of Washington
https://www.bakerlab.org